CERo Therapeutics Holdings, Inc. · OTC:CERO

CERo Therapeutics — Corporate Update (January 2026)

15 slides from CERo Therapeutics's corporate update, Jan 7, 2026

  1. Slide 1: CERTAINT-1 Trial Update

    January 7. 2026 CERTAINT - 1 Trial Update

  2. Slide 2: Disclaimer

    CERO This presentation (this “Presentation”) is provided for informational purposes only and for no other purpose and has been prepared to assist interested parties in making their own evaluation with respect to a potential investment in CERo The information contained herein is preliminary in nature

  3. Slide 3: What is a CER-T Cell?

    CERO 3 What is a CER - T Cell? himeric ngulfment eceptor C E R Uses TIM - 4 Phagocytic Receptor to Engage Tumor Targets via the Cell of Damaged Receptor TIM - 4 Ligand Tumor Cell TIM 4 Ligand T umor Cell CER - T Cell Multifunctional Construct Transmembrane Extracellular Domain Tumor binding and phag

  4. Slide 4: CERTAINT-1 Trial Design (Pre Amendment)

    CERO Cohort 1.1 1 x 10 6 cells/kg CER - 1236 Cohort 1.3s 5 x 10 6 cells/kg x 2 CER - 1236 START Cohort 1.2s 2.0 x 10 6 cells/kg x 2 CER - 1236 Cohort 2.1 – R/R AML 7 + 11 patients in each cohort Cohort 1.0 0.3 x 10 6 CER - 1236 Part 1 (Dose Escalation) Part 2 (Dose Expansion) Cohort 2.2 – cCR MRD+ A

  5. Slide 5: Three Key Findings in Current Program

    CERO Three Key Findings in Current Program 1. Robust cell expansion with no CRS, ICANS, or treatment - related adverse events reported to date. 2. Repeat dosing is feasible without LD. 3. Platelet recovery observed in patient 2 with MDS/AML. 5

  6. Slide 6: Robust Cell Expansion With No CRS, ICANS, Or Treatment-related Adverse Events

    CERO 1. Robust Cell Expansion With No CRS, ICANS, Or Treatment - related Adverse Events Reported To Date • No CRS reported to date in all 4 patients • No ICANS reported to date in all 4 patients 6

  7. Slide 7: Repeat dosing is feasible without LD

    CERO 2. Repeat dosing is feasible without LD • Several fold cell expansion observed after reinfusion without lymphodepletion. 7

  8. Slide 8: Patient 2 – MDS/AML

    CERO Patient 2 – MDS/AML • 74 year old man with MDS progressing to AML • Karyotype 46,XY,inv(3)(q21q26.2)x2[18]/44~46,idem[cp2] • FISH positive for MECOM (EVI1) rearrangement consistent with inv(3) • Never achieved marrow CR with standard or experimental treatments Response # Cycles Therapy No objec

  9. Slide 9: Patient – Multidose Treatment Course

    CERO Patient 2 – Multidose Treatment Course Infusions of 1e6 cells/kg 1 2 3 4 9

  10. Slide 10: Platelet recovery observed in patient 2 with MDS/AML

    CERO LD + CER - 1236 CER - 1236 CER - 1236 Platelet Tx Platelet Tx LD + CER - 1236 61 days 3. Platelet recovery observed in patient 2 with MDS/AML • Platelet and RBC transfusion dependent prior to CER - 1236 • A 61 - day platelet transfusion - free interval - exceeding the commonly used 8 - week thr

  11. Slide 11: Patient Hematological Indices

    CERO Patient 2 - Hematological Indices -50 0 50 100 150 20 40 60 80 100 Platelets Day x 1 0 ^ 3 / μ l -50 0 50 100 150 6 7 8 9 10 Hemoglobin Day g / d L 11

  12. Slide 12: Planned Next Steps

    CERO 12 Planned Next Steps x Protocol amended in December to include additional indications x Completed source data verification of foundational datasets x Engaged in exploratory discussions with potential partners at ASH □ Evaluating submission of data for scientific publication

  13. Slide 13: Opportunities in Myelodysplastic Syndrome (MDS)

    CERO Opportunities in Myelodysplastic Syndrome (MDS) • HMAs (azacitidine/decitabine) remain the only approved disease - modifying therapies in higher - risk MDS • The VERONA trial did not demonstrate an overall survival benefit for venetoclax added to HMAs • Observed transfusion independence (e.g.,

  14. Slide 14: Current Trial Amendment

    CERO Cohort 1.1 1 x 10 6 cells/kg CER - 1236 Cohort 1.3s 5 x 10 6 cells/kg x 2 CER - 1236 START Cohort 1.2s 2.0 x 10 6 cells/kg x 2 CER - 1236 Cohort 2.1 – R/R AML Cohort 1.0 0.3 x 10 6 CER - 1236 Part 1 (Dose Escalation) Part 2 (Dose Expansion) Cohort 2.2 – cCR MRD+ AML Cohort 2.3 – TP53 - Mutated

  15. Slide 15: Thank You

    CERO) ll © i i Thank You cn Ea S00 00000 ee — 4a eaaaonaee > See

CERo Therapeutics Holdings — Corporate Update (January 2026) on 6ix